Epidemiology and Risk Factors for Ovarian Cancer

Singla, Anshuja

doi:10.1007/978-981-13-3438-2_17

Cited by 4 publications

(2 citation statements)

References 72 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Increasing risk of OC has been observed in patients with a larger number of ovulatory cycles like patients with younger age at menarche and late age of menopause. Increasing the number of ovulatory cycles increases cellular divisions predisposing to the development of malignant neoplasms (10,11). OC is considered mainly postmenopausal disease.…”

mentioning

confidence: 99%

Epidemiology of ovarian cancer

2020

View full text Add to dashboard Cite

Worldwide, ovarian cancer (OC) is the seventh most common type of malignant neoplasm in women and the eighth cause of mortality in them. The classification of OC is made by the possible origin of one of the three main components of the ovary: epithelium, stroma, and germinal cells. Due to this the main malignant tumors arising from the ovary are epithelial carcinoma, germ cell tumor, sex cord-stromal tumor, and Krukenberg's tumor. The most common are the epithelial carcinomas, in which the most prevalent is serous ovarian carcinoma. Nevertheless, the subtype of OC varies according to the age of appearance. The global incidence of OC has been stable during the last decades, but, it's still a disease that has contributed to a considerable number of deaths around the world. The epidemiology of this cancer shows differences between races and countries due to several factors including genetic and economic. The detection of this cancer has been problematic as there is no screening public program for its early detection and as a consequence, most OCs are detected in an advanced stage where most of the time it has already spread to other parts different from the ovary. The purpose of this article is to present a comprehensive review of the general epidemiology, incidence rates, prevalence rates, mortality, and survival of the different types of OC worldwide and in certain regions.

show abstract

mentioning

confidence: 99%

Epidemiology of ovarian cancer

2020

View full text Add to dashboard Cite

show abstract

“…The most impactful ones are advanced age, genetic predisposition, and a family history of cancer. These factors are particularly related to continuous ovulation, hormonal changes, cumulative genetic damage, and chronic inflammation [3,[25][26][27]. Ovarian tumours are rare among young women, particularly those under the age of 30.…”

Section: Disease Aetiology and Preventionmentioning

confidence: 99%

Paradigm Shift: A Comprehensive Review of Ovarian Cancer Management in an Era of Advancements

Tavares,

Marques,

Melo

et al. 2024

IJMS

View full text Add to dashboard Cite

Ovarian cancer (OC) is the female genital malignancy with the highest lethality. Patients present a poor prognosis mainly due to the late clinical presentation allied with the common acquisition of chemoresistance and a high rate of tumour recurrence. Effective screening, accurate diagnosis, and personalised multidisciplinary treatments are crucial for improving patients’ survival and quality of life. This comprehensive narrative review aims to describe the current knowledge on the aetiology, prevention, diagnosis, and treatment of OC, highlighting the latest significant advancements and future directions. Traditionally, OC treatment involves the combination of cytoreductive surgery and platinum-based chemotherapy. Although more therapeutical approaches have been developed, the lack of established predictive biomarkers to guide disease management has led to only marginal improvements in progression-free survival (PFS) while patients face an increasing level of toxicity. Fortunately, because of a better overall understanding of ovarian tumourigenesis and advancements in the disease’s (epi)genetic and molecular profiling, a paradigm shift has emerged with the identification of new disease biomarkers and the proposal of targeted therapeutic approaches to postpone disease recurrence and decrease side effects, while increasing patients’ survival. Despite this progress, several challenges in disease management, including disease heterogeneity and drug resistance, still need to be overcome.

show abstract